

# Axel Grothey

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6865314/publications.pdf](https://exaly.com/author-pdf/6865314/publications.pdf)

Version: 2024-02-01

244  
papers

28,812  
citations

14615

66  
h-index

5713

163  
g-index

275  
all docs

275  
docs citations

275  
times ranked

38142  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 303-312.	12.1	2,360
2	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	12.1	1,443
3	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3219-3226.	15.4	1,398
4	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3677-3683.	15.4	1,193
5	Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. <i>Journal of Clinical Oncology</i> , 2006, 24, 2903-2909.	15.4	1,066
6	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	30.1	1,020
7	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. <i>Journal of Clinical Oncology</i> , 2004, 22, 1209-1214.	15.4	1,011
8	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2015, 16, 499-508.	10.8	779
9	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	30.1	750
10	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 874-901.	10.4	729
11	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 370-398.	10.4	726
12	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 359-369.	10.4	715
13	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). <i>Journal of Clinical Oncology</i> , 2008, 26, 5326-5334.	15.4	657
14	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	15.4	617
15	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	7.3	586
16	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	15.4	556
17	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	4.1	533
18	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , 2016, 17, 1709-1719.	10.8	479

#	ARTICLE	IF	CITATIONS
19	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	7.0	419
20	Cyclooxygenase-2: a novel target for cancer chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 411-417.	2.6	382
21	Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement. <i>Annals of Surgical Oncology</i> , 2006, 13, 1261-1268.	2.0	341
22	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 507-518.	27.6	337
23	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. <i>Oncologist</i> , 2009, 14, 862-870.	4.1	296
24	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	10.8	294
25	Biomarkers and surrogate end points—the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 309-317.	27.6	287
26	<sup>Non-V600</sup> BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630.	15.4	281
27	5-fluorouracil and cardiotoxicity: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878014.	3.4	273
28	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	10.8	264
29	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4217-4223.	15.4	259
30	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3416-3422.	15.4	231
31	A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 811-821.	1.2	230
32	Drug rechallenge and treatment beyond progression—implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 571-587.	27.6	228
33	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2007, 12, 38-50.	4.1	219
34	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010, 28, 3227-3233.	15.4	201
35	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	15.4	196
36	Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 997-1005.	15.4	191

#	ARTICLE	IF	CITATIONS
37	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	10.4	185
38	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	3.5	183
39	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	10.8	182
40	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	15.4	172
41	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Lancet Oncology, The, 2020, 21, 1620-1629.	10.8	170
42	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	15.4	163
43	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	6.4	144
44	Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti-epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 29-31.	2.4	141
45	Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas. Clinical Cancer Research, 2012, 18, 546-554.	7.2	132
46	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	3.4	126
47	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs, 2017, 77, 1091-1103.	11.1	121
48	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. International Journal of Cancer, 2020, 147, 2948-2956.	5.4	114
49	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 852-871.	10.4	110
50	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene, 2000, 19, 4864-4875.	5.9	107
51	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	15.4	104
52	Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs, 2000, 11, 225-236.	1.4	102
53	A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2159-2170.	1.9	98
54	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1936-1941.	15.4	97

#	ARTICLE	IF	CITATIONS
55	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019, 24, 185-192.	4.1	96
56	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 Months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	0.5	95
57	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , 2015, 33, 740-750.	2.7	95
58	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. <i>Lancet Oncology</i> , The, 2016, 17, 663-670.	10.8	92
59	Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX+Bevacizumab or FOLFIRI+Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. <i>Oncologist</i> , 2012, 17, 1486-1495.	4.1	91
60	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	15.4	88
61	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 933-946.	8.2	88
62	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.4	87
63	Randomized Phase II Trials: Inevitable or Inadvisable?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2641-2647.	15.4	79
64	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	4.4	72
65	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	15.4	71
66	A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES. <i>Retina</i> , 2012, 32, 1959-1966.	1.9	71
67	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). <i>Supportive Care in Cancer</i> , 2016, 24, 5059-5068.	2.3	71
68	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	7.0	70
69	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	8.0	68
70	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.4	67
71	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 3656-3663.	15.4	66
72	Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 170-177.	2.0	65

#	ARTICLE	IF	CITATIONS
73	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv216.	6.4	65
74	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. <i>Oncologist</i> , 2014, 19, 669-680.	4.1	62
75	New chemotherapy approaches in colorectal cancer. <i>Current Opinion in Oncology</i> , 2001, 13, 275-286.	2.5	58
76	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016, 16, 467.	2.6	57
77	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. <i>European Journal of Haematology</i> , 2005, 74, 263-266.	2.2	56
78	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 653-659.	8.0	52
79	Adolescent and Young Adult Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1219-1225.	10.4	50
80	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. <i>Supportive Care in Cancer</i> , 2016, 24, 1071-1078.	2.3	50
81	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. <i>Molecular Therapy</i> , 2008, 16, 979-984.	8.1	46
82	Clinical Trial Designs for Prospective Validation of Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 317-325.	3.5	45
83	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7492-7501.	7.2	45
84	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 726-734.	1.9	45
85	Curable Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2011, 13, 168-176.	4.1	43
86	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	15.4	43
87	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 1083-1091.	4.1	43
88	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. <i>Journal of Clinical Oncology</i> , 2014, 32, 841-850.	15.4	42
89	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. <i>Drugs</i> , 2018, 78, 737-745.	11.1	42
90	ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i> <sup>V600E</sup> -Mutant Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2628-2637.	15.4	42



#	ARTICLE	IF	CITATIONS
91	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. <i>Clinical Colorectal Cancer</i> , 2014, 13, 100-109.	2.4	41
92	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	3.2	41
93	Landscape of <i>KRAS</i> <sup>G12C</sup> , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i> -Mutated Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100245.	3.2	40
94	Progress in defining first-line and maintenance therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 73-74.	27.6	39
95	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 124-128.	2.4	38
96	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 106-126.	3.4	38
97	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1083-1090.	4.1	37
98	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	4.1	37
99	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016, 21, 1509-1521.	4.1	37
100	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. <i>Frontiers in Oncology</i> , 2019, 9, 76.	2.9	37
101	Treatment options for advanced pancreatic cancer: a review. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1327-1336.	2.6	36
102	Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> <sup>V600E</sup> Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 128-134.	4.1	35
103	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. <i>Clinical Colorectal Cancer</i> , 2019, 18, 52-57.	2.4	34
104	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	7.2	34
105	Targeting colorectal cancer with human anti-EGFR monoclonal antibodies: focus on panitumumab. <i>Biologics: Targets and Therapy</i> , 2008, 2, 223.	3.5	33
106	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	15.4	33
107	A new prognostic and predictive tool for shared decision making in stage III colon cancer. <i>European Journal of Cancer</i> , 2020, 138, 182-188.	2.9	33
108	Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications. <i>Oncologist</i> , 2012, 17, 725-731.	4.1	32

#	ARTICLE	IF	CITATIONS
109	MODULâ€”a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1197-1204.	2.6	32
110	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	2.9	32
111	Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 199-204.	2.0	31
112	Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland. <i>Medizinische Klinik</i> , 2002, 97, 270-277.	0.3	29
113	N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 211-213.	2.4	29
114	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). <i>Cancer</i> , 2007, 110, 670-677.	4.1	29
115	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. <i>Clinical Colorectal Cancer</i> , 2004, 4, 46-50.	2.4	28
116	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 60-64.	2.4	28
117	Antiangiogenesis agents in colorectal cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 374-380.	2.5	28
118	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	4.1	27
119	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	4.4	27
120	Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial. <i>Clinical Colorectal Cancer</i> , 2006, 6, 261-264.	2.4	26
121	Prognostic webâ€”based models for stage II and III colon cancer. <i>Cancer</i> , 2011, 117, 4155-4165.	4.1	26
122	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 301-319.	3.4	26
123	Pembrolizumab in MSI-Hâ€”dMMR Advanced Colorectal Cancer â€” A New Standard of Care. <i>New England Journal of Medicine</i> , 2020, 383, 2283-2285.	30.1	26
124	Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 313-314.	27.6	25
125	Is obesity an advantage in patients with colorectal cancer?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1339-1342.	3.0	22
126	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 961-969.	2.4	22



#	ARTICLE	IF	CITATIONS
127	Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 267-276.	2.7	22
128	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. <i>Seminars in Oncology</i> , 2010, 37, 39-46.	2.3	21
129	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv239.	6.4	21
130	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. <i>Supportive Care in Cancer</i> , 2005, 13, 26-31.	2.3	19
131	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1451-1455.	6.6	19
132	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. <i>Oncologist</i> , 2018, 23, 679-685.	4.1	18
133	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 316-325.	7.2	18
134	Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 611-615.	10.4	18
135	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	1.8	18
136	First- and second-line therapy of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 921-930.	2.6	17
137	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. <i>ESMO Open</i> , 2021, 6, 100328.	4.4	17
138	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. <i>Oncologist</i> , 2011, 16, 859-867.	4.1	16
139	<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. <i>Oncologist</i> , 2011, 16, 1061-1068.	4.1	16
140	The search for treatments to reduce chemotherapy-induced peripheral neuropathy. <i>Journal of Clinical Investigation</i> , 2014, 124, 72-74.	8.2	16
141	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018, 3, e000347.	4.4	16
142	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	7.2	16
143	Diagnostisches und therapeutisches Management der oberen Einflusstauung. <i>Medizinische Klinik</i> , 1999, 94, 681-684.	0.3	15
144	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , 2017, Volume 9, 149-158.	2.0	15

#	ARTICLE	IF	CITATIONS
145	Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 171-176.	3.5	14
146	Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, S37-S42.	2.4	14
147	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091091.	3.4	14
148	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 383-402.	2.8	14
149	Future Directions in Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Colorectal Cancer. <i>Seminars in Oncology</i> , 2006, 33, S41-S49.	2.3	13
150	When less is more: maintenance therapy in colorectal cancer. <i>Lancet, The</i> , 2015, 385, 1808-1810.	12.1	13
151	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	2.9	13
152	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 96-100.	2.6	12
153	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, e183-e187.	2.4	12
154	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 1998, 9, 405-409.	1.4	11
155	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1097-1101.	10.4	11
156	Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 273-276.	3.0	11
157	Regorafenib in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 137-145.	1.9	11
158	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). <i>Journal of Geriatric Oncology</i> , 2018, 9, 24-31.	1.1	11
159	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	3.8	11
160	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1417-1427.	2.0	11
161	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. <i>Supportive Care in Cancer</i> , 2019, 27, 3869-3875.	2.3	10
162	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer- Fact or Fiction?. <i>JAMA Oncology</i> , 2020, 6, 823.	7.3	10

#	ARTICLE	IF	CITATIONS
163	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. <i>SOJ Anesthesiology &amp; Pain Management</i> , 2015, 2, .	0.1	10
164	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	5.5	10
165	Regorafenib for metastatic colorectal cancer – Authors' reply. <i>Lancet, The</i> , 2013, 381, 1538-1539.	12.1	9
166	VEGF inhibition beyond tumour progression. <i>Lancet Oncology, The</i> , 2013, 14, 2-3.	10.8	9
167	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110244.	3.2	9
168	Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. <i>Statistical Methods in Medical Research</i> , 2008, 17, 529-535.	1.6	8
169	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , 2015, 8, 2949.	2.1	8
170	Adjuvant Therapy for Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 1133.	7.3	8
171	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. <i>Lancet Oncology, The</i> , 2020, 21, 324-326.	10.8	8
172	Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2023, 184, 137-150.	2.9	8
173	Do All Patients with Metastatic Colorectal Cancer Need Chemotherapy Until Disease Progression?. <i>Clinical Colorectal Cancer</i> , 2006, 6, 196-201.	2.4	7
174	Review: Medical treatment of advanced colorectal cancer in 2009. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 55-68.	3.4	7
175	The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases. <i>Cancer Journal (Sudbury, Mass )</i> , 2010, 16, 125-131.	2.0	7
176	Does Stage II Colorectal Cancer Need to Be Redefined?. <i>Clinical Cancer Research</i> , 2011, 17, 3053-3055.	7.2	7
177	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). <i>American Journal of Hematology</i> , 2017, 92, 1004-1010.	4.3	7
178	Evolution of Cancer Care in Response to the COVID –19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427.	4.1	7
179	North Central Cancer Treatment Group – Achievements and Perspectives. <i>Seminars in Oncology</i> , 2008, 35, 530-544.	2.3	6
180	A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 10-11.	2.3	6

#	ARTICLE	IF	CITATIONS
181	Should Oncologists Routinely Discuss Fertility Preservation With Cancer Patients of Childbearing Age?. <i>Mayo Clinic Proceedings</i> , 2011, 86, 6-7.	2.8	6
182	The role of regorafenib in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 596-597.	10.8	6
183	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , 2021, Volume 13, 5523-5533.	2.0	6
184	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. <i>Annals of Surgical Oncology</i> , 2010, 17, 947-949.	2.0	5
185	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-7.	0.4	5
186	Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 885.	7.3	5
187	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019, 30, 757-765.	1.8	5
188	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100492.	1.1	5
189	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	4.1	5
190	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021, 26, 651-659.	4.1	5
191	Microsatellite Stable Colorectal Liver Metastases—Understanding the Mechanisms of Immune Resistance. <i>JAMA Network Open</i> , 2021, 4, e2119025.	6.0	5
192	Developments in combination chemotherapy for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 627-637.	2.6	4
193	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. <i>Hpb</i> , 2013, 15, 116-118.	0.3	4
194	Phase III Randomized, Placebo(PI)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1. <i>Annals of Oncology</i> , 2013, 24, iv24.	1.3	4
195	Metastatic extramammary Paget's disease responding to weekly paclitaxel. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208653.	0.5	4
196	Personalizing Treatment for Rectal Cancer. <i>JAMA Network Open</i> , 2020, 3, e2030508.	6.0	4
197	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. <i>Anti-Cancer Drugs</i> , 1999, 10, 545-550.	1.4	3
198	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010, 28, e652-e653.	15.4	3

#	ARTICLE	IF	CITATIONS
199	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.4	3
200	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 55-68.	0.5	3
201	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.8	3
202	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 3191-3193.	15.4	2
203	Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 682-685.	10.4	2
204	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 326-334.	0.5	2
205	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103.	2.7	2
206	Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. <i>Lancet Oncology</i> , The, 2017, 18, 1427-1428.	10.8	2
207	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	6.4	2
208	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 22-23.	2.3	1
209	Reply to S.A. Kesikli et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2288-2289.	15.4	1
210	O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC). <i>Annals of Oncology</i> , 2012, 23, iv15-iv16.	1.3	1
211	The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt442-djt442.	6.4	1
212	Distinctive Tumor Biology of MSI-High Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 281-287.	0.5	1
213	Colorectal cancer: how to teach an old drug new tricks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 384-385.	18.1	1
214	Adverse event development in clinical oncology trials – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e264-e265.	10.8	1
215	Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting. <i>Gynecologic Oncology</i> , 2021, 162, S180.	1.4	1
216	Does Lifestyle Cause Colorectal Cancer?. , 2006, , 1-13.		1

#	ARTICLE	IF	CITATIONS
217	The Role of the Colorectal Nurse Specialist in the Management of Colorectal Cancer. , 2006, , 153-166.		1
218	Minimally Invasive Surgery “ Where are We? is there a Role for TEM?. , 2006, , 73-88.		1
219	The Role of the Multidisciplinary Team in the Management of Colorectal Cancer. , 2006, , 167-177.		1
220	Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. European Journal of Cancer, 2023, 178, 162-170.	2.9	1
221	Should bevacizumab be continued beyond progression in colorectal cancer?. Current Colorectal Cancer Reports, 2008, 4, 139-143.	0.5	0
222	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	15.4	0
223	Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. Current Colorectal Cancer Reports, 2009, 5, 65-66.	0.5	0
224	Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. Current Colorectal Cancer Reports, 2010, 6, 126-132.	0.5	0
225	Recent developments in therapy for gastrointestinal cancers. Community Oncology, 2011, 8, 4-8.	0.1	0
226	Adjuvant Hepatic Arterial Infusional Chemotherapy. Annals of Surgery, 2011, 254, 857-859.	4.5	0
227	Reduced Chemotherapy Duration: A Good Idea?. Current Colorectal Cancer Reports, 2011, 7, 241-245.	0.5	0
228	Reply to A. Chan et al. Journal of Clinical Oncology, 2011, 29, e490-e491.	15.4	0
229	Reply to M. MandalÃ et al. Journal of Clinical Oncology, 2012, 30, 1895-1895.	15.4	0
230	Establishing a Standard of Care for Small Bowel Adenocarcinomas: Challenges and Lessons Learned. Oncologist, 2012, 17, 1133-1134.	4.1	0
231	S-1 in colorectal cancer: a new standard of care?. Lancet Oncology, The, 2012, 13, 1068-1070.	10.8	0
232	Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability“High Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 36-41.	0.5	0
233	European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Therapeutic Advances in Medical Oncology, 2017, 9, 4-12.	3.4	0
234	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	1.5	0

#	ARTICLE	IF	CITATIONS
235	Follow-up after Colorectal Cancer Resection: Is it Worth While?. , 2006, , 178-194.		0
236	Surgery for Metastatic Disease in Colorectal Cancer. , 2006, , 213-231.		0
237	Palliative Care of the Colorectal Cancer Patient. , 2006, , 232-250.		0
238	Future Directions in the Oncological Treatment of Colorectal Cancer. , 2006, , 251-270.		0
239	Screening for Colorectal Cancer â€” Who, When, and How?. , 2006, , 14-30.		0
240	What can the Pathologist Tell the Multidisciplinary Team about Rectal Cancer Resection?. , 2006, , 31-45.		0
241	MRI-directed Rectal Cancer Surgery. , 2006, , 46-59.		0
242	Minimally Invasive Surgery â€” Where are We? Laparoscopic Surgery for Cancer of the Colon and Rectum. , 2006, , 60-72.		0
243	What is the Best Strategy for the Management of Hereditary Colorectal Cancer?. , 2006, , 89-111.		0
244	Adjuvant Radiotherapy and Chemoradiotherapy in the Treatment of Rectal Cancer. , 2006, , 112-132.		0